晚期肾细胞癌的免疫治疗现状与进展

doi:10.3760/cma.j.cn371439-20240820-00019

摘要/Abstract

摘要：

约25%的肾细胞癌（RCC）患者在初诊时就已处于晚期，并且有近30%局限性RCC患者在根治性手术后仍发生远处转移。传统的化疗以及放疗方案对晚期RCC患者的治疗效果十分有限，因此晚期RCC患者的预后较差，5年生存率约为8%。近几年RCC的免疫治疗成为了研究热点，随着研究的不断深入，晚期RCC患者的治疗越来越多样化。探讨晚期RCC的免疫治疗的临床应用现状以及相关研究进展，可以为晚期RCC患者治疗方案的选择提供医学证据。

关键词: 癌，肾细胞, 免疫疗法, 免疫检查点抑制剂

Abstract:

Approximately 25% of renal cell carcinoma （RCC） patients are already at an advanced stage at the time of initial diagnosis. Additionally， nearly 30% of patients with localized RCC eventually develop distant metastases even after undergoing radical surgery. Traditional chemotherapy and radiotherapy have shown limited effect on advanced RCC treatment， resulting in poor prognosis， with a 5-year survival rate of only about 8%. In recent years， immunotherapy for RCC has become a significant focus of research. With further research， the treatment options for advanced RCC have become increasingly diverse. The exploration of the current clinical applications and research advancements in immunotherapy for advanced RCC could offer medical evidence for optimizing treatment strategies for advanced RCC patients.

Key words: Carcinoma， renal cell, Immunotherapy, Immune checkpoint inhibitor

陈茹雁, 付振明. 晚期肾细胞癌的免疫治疗现状与进展[J]. 国际肿瘤学杂志, 2025, 52(2): 124-128.

Chen Ruyan, Fu Zhenming. Current status and advances in immunotherapy for advanced renal cell carcinoma[J]. Journal of International Oncology, 2025, 52(2): 124-128.

参考文献 46

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Wang Z, Wang L, Wang S, et al. Burden of kidney cancer and attributed risk factors in China from 1990 to 2019[J]. Front Public Health, 2022, 10: 1062504. DOI: 10.3389/fpubh.2022.1062504.
[3]	Campi R, Rebez G, Klatte T, et al. Effect of smoking, hypertension and lifestyle factors on kidney cancer-perspectives for prevention and screening programmes[J]. Nat Rev Urol, 2023, 20(11): 669-681. DOI: 10.1038/s41585-023-00781-8.
[4]	Pal S, Gong J, Mhatre SK, et al. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database[J]. BMC Cancer, 2019, 19(1): 548. DOI: 10.1186/s12885-019-5716-z. pmid: 31174493
[5]	D'Avella C, Abbosh P, Pal SK, et al. Mutations in renal cell carcinoma[J]. Urol Oncol, 2020, 38(10): 763-773. DOI: 10.1016/j.urolonc.2018.10.027. pmid: 30478013
[6]	Braun DA, Bakouny Z, Hirsch L, et al. Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma[J]. Nat Rev Clin Oncol, 2021, 18(4): 199-214. DOI: 10.1038/s41571-020-00455-z.
[7]	Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion[J]. Nat Rev Cancer, 2021, 21(5): 298-312. DOI: 10.1038/s41568-021-00339-z. pmid: 33750922
[8]	Chen Y, Yu D, Qian H, et al. CD8⁺ T cell-based cancer immunotherapy[J]. J Transl Med, 2024, 22(1): 394. DOI: 10.1186/s12967-024-05134-6.
[9]	岳红云, 张百红. 免疫检查点激动剂治疗实体瘤的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 290-293. DOI: 10.3760/cma.j.cn371439-20220726-00058.
[10]	Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons[J]. Cell Commun Signal, 2022, 20(1): 44. DOI: 10.1186/s12964-022-00854-y.
[11]	Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223-249. DOI: 10.1146/annurev-pathol-042020-042741. pmid: 33197221
[12]	曹梦清, 徐志勇, 施毓婷, 等. 三级淋巴结构在肿瘤免疫微环境调节和抗肿瘤治疗中的作用[J]. 国际肿瘤学杂志, 2023, 50(3): 169-173. DOI: 10.3760/cma.j.cn371439-20221121-00033.
[13]	Salmaninejad A, Valilou SF, Shabgah AG, et al. PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy[J]. J Cell Physiol, 2019, 234(10): 16824-16837. DOI: 10.1002/jcp.28358. pmid: 30784085
[14]	Liu J, Chen Z, Li Y, et al. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy[J]. Front Pharmacol, 2021, 12: 731798. DOI: 10.3389/fphar.2021.731798.
[15]	Bosnali E, Akdas EM, Telli E, et al. The role of immunotherapy in urological cancers[J]. Arch Ital Urol Androl, 2024, 96(2): 12307. DOI:10.4081/aiua.2024.12307.
[16]	Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813. DOI: 10.1056/NEJMoa1510665.
[17]	Liu Y, Zheng P. Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy[J]. Trends Pharmacol Sci, 2020, 41(1): 4-12. DOI: 10.1016/j.tips.2019.11.003. pmid: 31836191
[18]	Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis[J]. J Immunother, 2007, 30(8): 825-830.DOI:10.1097/CJI.0b013e318156e47e. pmid: 18049334
[19]	Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review[J]. Eur J Cancer, 2016, 54: 139-148. DOI: 10.1016/j.ejca.2015.11.016. pmid: 26765102
[20]	Chen C, Wu B, Zhang C, et al. Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system[J]. Int Immunopharmacol, 2021, 95: 107498. DOI: 10.1016/j.intimp.2021.107498.
[21]	Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290. DOI: 10.1056/NEJMoa1712126.
[22]	Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma[J]. Cancer, 2022, 128(11): 2085-2097. DOI: 10.1002/cncr.34180.
[23]	Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention[J]. Signal Transduct Target Ther, 2021, 6(1): 263. DOI: 10.1038/s41392-021-00658-5.
[24]	Tamura R, Tanaka T, Akasaki Y, et al. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications[J]. Med Oncol, 2019, 37(1): 2. DOI: 10.1007/s12032-019-1329-2. pmid: 31713115
[25]	Zheng R, Li F, Li F, et al. Targeting tumor vascularization: promi-sing strategies for vascular normalization[J]. J Cancer Res Clin Oncol, 2021, 147(9): 2489-2505. DOI: 10.1007/s00432-021-03701-8.
[26]	Liu Z, Wang Y, Huang Y, et al. Tumor vasculatures: a new target for cancer immunotherapy[J]. Trends Pharmacol Sci, 2019, 40(9): 613-623. DOI: 10.1016/j.tips.2019.07.001. pmid: 31331639
[27]	Mpekris F, Voutouri C, Baish JW, et al. Combining microenvironment normalization strategies to improve cancer immunotherapy[J]. Proc Natl Acad Sci U S A, 2020, 117(7): 3728-3737. DOI: 10.1073/pnas.1919764117.
[28]	Tzeng HT, Huang YJ. Tumor vasculature as an emerging pharmacological target to promote anti-tumor immunity[J]. Int J Mol Sci, 2023, 24(5): 4422. DOI: 10.3390/ijms24054422.
[29]	Cella D, Motzer RJ, Suarez C, et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 292-303. DOI: 10.1016/s1470-2045(21)00693-8. pmid: 35032437
[30]	Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23(7): 888-898. DOI: 10.1016/s1470-2045(22)00290-x. pmid: 35688173
[31]	Powles T, Burotto M, Escudier B, et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase Ⅲ randomised CheckMate 9ER trial[J]. ESMO Open, 2024, 9(5): 102994. DOI: 10.1016/j.esmoop.2024.102994.
[32]	Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1103-1115. DOI: 10.1056/NEJMoa1816047.
[33]	Tomita Y, Motzer RJ, Choueiri TK, et al. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN renal 101[J]. ESMO Open, 2023, 8(6): 102034. DOI: 10.1016/j.esmoop.2023.102034.
[34]	Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma[J]. Ann Oncol, 2020, 31(8): 1030-1039. DOI: 10.1016/j.annonc.2020.04.010. pmid: 32339648
[35]	Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1116-1127. DOI: 10.1056/NEJMoa1816714.
[36]	Plimack ER, Powles T, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study[J]. Eur Urol, 2023, 84(5): 449-454. DOI: 10.1016/j.eururo.2023.06.006. pmid: 37500340
[37]	Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(12): 1563-1573. DOI: 10.1016/s1470-2045(20)30436-8. pmid: 33284113
[38]	Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300. DOI: 10.1056/NEJMoa2035716.
[39]	Motzer RJ, Porta C, Eto M, et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase Ⅲ study[J]. J Clin Oncol, 2024, 42(11): 1222-1228. DOI: 10.1200/jco.23.01569.
[40]	Motzer RJ, Jonasch E, Agarwal N, et al. NCCN guidelines^® insights: kidney cancer, version 2.2024[J]. J Natl Compr Canc Netw, 2024, 22(1): 4-16. DOI: 10.6004/jnccn.2024.0008.
[41]	Apolo AB, Powles T, Escudier B, et al. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: results from a discontinued arm of the phase Ⅲ checkmate 9ER trial[J]. Eur J Cancer, 2022, 177: 63-71. DOI: 10.1016/j.ejca.2022.09.020.
[42]	Choueiri TK, Wang F, Motzer RJ. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. Reply[J]. N Engl J Med, 2023, 389(5): 477-478. DOI: 10.1056/NEJMc2306786.
[43]	National Cancer Institute. Study of sitravatinib, nivolumab and ipilimumab in advanced or metastatic clear-cell renal cell carcinoma or other solid malignancies[EB/OL]. (2024-06-05)[2024-09-11]. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2020-06868.
[44]	MSD. A study of pembrolizumab (MK-3475) in combination with belzutifan (MK-6482) and lenvatinib (MK-7902), or pembrolizumab/quavonlimab (MK-1308A) in combination with lenvatinib, versus pembrolizumab and lenvatinib, for treatment of advanced clear cell renal cell carcinoma (MK-6482-012)[EB/OL]. (2024-03-12)[2024-09-11]. https://ctv.veeva.com/study/a-study-of-pembrolizumab-mk-3475-in-combination-with-belzutifan-mk-6482-and-lenvatinib-mk7902.
[45]	National Cancer Institute. A study to evaluate MEDI5752 and axitinib in subjects with advanced renal cell carcinoma[EB/OL]. (2024-06-25)[2024-09-11]. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2020-08221&r=1.
[46]	National Cancer Institute. Immunotherapy with nivolumab and ipilimumab followed by nivolumab or nivolumab with cabozantinib for patients with advanced kidney cancer, the PDIGREE study[EB/OL]. (2024-08-16)[2024-09-11]. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2018-03694&r=1.